Get the Stockscreener App
8.57
1.38%
-0.12
After Hours:
8.60
0.03
+0.35%
Biocryst Pharmaceuticals Inc stock is traded at $8.57, with a volume of 4.89M.
It is down -1.38% in the last 24 hours and up +33.49% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.69
Open:
$8.66
24h Volume:
4.89M
Relative Volume:
1.13
Market Cap:
$2.13B
Revenue:
$557.51M
Net Income/Loss:
$-35.71M
P/E Ratio:
-47.61
EPS:
-0.18
Net Cash Flow:
$15.50M
1W Performance:
+13.51%
1M Performance:
+33.49%
6M Performance:
+3.63%
1Y Performance:
+3.13%
1-Day Range:
$8.385
$8.72
1-Week Range:
$7.59
$8.86
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.57 | 2.16B | 557.51M | -35.71M | 15.50M | -0.18 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Resumed | Evercore ISI | Outperform |
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst (BCRX) Grants Stock Units to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Director Jill C. Milne receives 528 BCRX shares as board retainer grant - Stock Titan
Biocryst (NASDAQ: BCRX) director executes option exercise and share disposition - Stock Titan
Director Vincent Milano gets 848 BIOCRYST (BCRX) shares as equity retainer - Stock Titan
BIOCRYST (BCRX) director Steven Frank receives 1,285-share stock retainer grant - Stock Titan
Director Amy McKee receives stock retainer award at BioCryst (BCRX) - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 146.81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio ExpansionHas The Bull Case Changed? - Sahm
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com India
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next - TechStock²
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story - Yahoo Finance
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
BioCryst (BCRX) Soars 10.8% on Swing to Profits - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
BioCryst Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCRX SEC FilingsBiocryst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat - MarketBeat
Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
10 Stocks Ending February With a Bang - Insider Monkey
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Inc (BCRX): A Strategic SWOT Insight - GuruFocus
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Yahoo Finance
BioCryst: Q4 Earnings Snapshot - theheraldreview.com
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highli - GuruFocus
BCRX: $400M Blackstone term loan funds Astria deal, secured by assets, matures 2031, SOFR+4.5% - TradingView
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth By Investing.com - Investing.com South Africa
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS - MarketBeat
BioCryst Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-02-26 - Seeking Alpha
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioCryst Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Earnings call transcript: BioCryst Q4 2025 sees EPS and revenue beat - Investing.com
BioCryst Pharmaceuticals' Q4 Swings to Earnings; Revenue Rises - marketscreener.com
BIOCRYST PHARMACEUTICALS ($BCRX) Releases Q4 2025 Earnings - Quiver Quantitative
Q4 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 Total Revenue $406.6M - marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 EPS $1.12 - marketscreener.com
BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance - TipRanks
BioCryst: Fourth Quarter Financial Highlights - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Pharmaceuticals (BCRX) Projects Orladeyo Revenue to Rea - GuruFocus
BioCryst Pharmaceuticals : BCRX Q4 2025 Earnings Presentation - marketscreener.com
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ... By GuruFocus - Investing.com Canada
Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound - Yahoo Finance
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):